top of page

Poster: CST6 cmRNA delivery for bone regeneration

Updated: Nov 2, 2023



Authors: Pornpoj Phruttiwanichakun; Rui He; Sainiket Panyam; Aliasger K. Salem


Introduction

Critical-sized bone defects are large bone defects that tend not to heal, necessitating reconstructive surgeries with bone grafting being the preferred procedure. Conventional bone grafting procedures face challenges such as donor site morbidity, the need for additional surgeries, and risk of graft rejection (for allografts). Of various alternatives to conventional bone grafts, biodegradable implants for local delivery of osteogenic growth factors or osteogenic mRNA have gained much attention in bone regeneration research. Recently, cystatin E/M (CST6), an endogenous cysteine protease inhibitor, has been shown to inhibit osteoclast differentiation and osteoclast mediated bone resorption. However, CST6 and its effects osteoblast differentiation and bone matrix mineralization have not been explored. Herein, recombinant human CST6 (rhCST6) and rhCST6-encoding chemically modified mRNA (CST6-cmRNA) were investigated for their possible novel functions in promoting osteogenesis and/or bone matrix mineralization.




Keywords: Lipid nanoparticle (LNP) , CST6, LNP-mRNA, Drug delivery, CST6 cmRNA, bone regeneration, CST6-cmRNA


Nanomedicine and Drug Delivery Symposium (NanoDDS) 2023 @MIT

Comments


bottom of page